These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 7601292)

  • 1. Effects of long-term administration of a combined alpha- and beta-adrenoceptor blocking agent on glucose and lipid metabolisms in patients with non-insulin-dependent diabetes mellitus.
    Okada S; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1995; 23(2):106-11. PubMed ID: 7601292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alpha-adrenergic blockade on blood pressure, glucose, and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Maruyama H; Saruta T; Itoh H; Koyama K; Kido K; Itoh K; Takei I; Kataoka K
    Am Heart J; 1991 Apr; 121(4 Pt 2):1302-6. PubMed ID: 1672575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension].
    Balabolkin MI; Khasanova ER; Trukhina TV; Kreminskaia VM
    Ter Arkh; 2002; 74(12):38-41. PubMed ID: 12577838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.
    Whitcroft IA; Thomas JM; Rawsthorne A; Wilkinson N; Thompson H
    Horm Metab Res Suppl; 1990; 22():42-6. PubMed ID: 1975246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
    Jacob S; Rett K; Wicklmayr M; Agrawal B; Augustin HJ; Dietze GJ
    J Hypertens; 1996 Apr; 14(4):489-94. PubMed ID: 8761899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism.
    Inukai T; Inukai Y; Matsutomo R; Okumura K; Takanashi K; Takebayashi K; Tayama K; Aso Y; Takemura Y
    J Int Med Res; 2004; 32(2):206-13. PubMed ID: 15080025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Atarashi K; Takagi M; Minami M; Kimura Y; Matsuoka H; Sugimoto T
    Blood Press Suppl; 1992; 3():130-4. PubMed ID: 1343282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus].
    Vulpis V; Antonacci A; Prandi P; Bokor D; Pirrelli A
    Minerva Med; 1991 Apr; 82(4):189-93. PubMed ID: 1673233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM).
    Oren S; Turkot S; Paran E; Flandra O; Slezak L; Hof B
    J Hum Hypertens; 1996 Feb; 10(2):123-7. PubMed ID: 8867567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
    Middeke M; Richter WO; Schwandt P; Holzgreve H
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.
    Wago T; Yoshimoto T; Akaza I; Tsuchiya K; Izumiyama H; Doi M; Hirata Y
    Hypertens Res; 2010 Aug; 33(8):796-801. PubMed ID: 20555330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of diuretic and beta-blocker treatment of hypertension in patients with non-insulin-dependent diabetes mellitus.
    Fuh MM; Sheu WH; Shen DC; Wu DA; Chen YD; Reaven GM
    Am J Hypertens; 1990 May; 3(5 Pt 1):387-90. PubMed ID: 1972024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
    Pasanisi F; Imperatore G; Vaccaro O; Iovine C; Ferrara LA
    Nutr Metab Cardiovasc Dis; 1999 Apr; 9(2):73-7. PubMed ID: 10726112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
    Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive and metabolic effects of long-term treatment with amosulalol in non-insulin dependent diabetics.
    Inoue Y; Yaga K; Nishimura M; Okafuji K; Fujii Y; Nagasaka Y; Tanaka M; Fujita N; Kaku K; Kaneko T
    Curr Med Res Opin; 1992; 12(9):564-71. PubMed ID: 1582238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
    Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
    J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.